Log In
Print this Print this

Biosimilar ranibizumab (CHS-3351)

  Manage Alerts
Collapse Summary General Information
Company Coherus BioSciences Inc.
DescriptionBiosimilar of ranibizumab, a mAb fragment against VEGF-A
Molecular Target Vascular endothelial growth factor A (VEGF-A)
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat neovascular age-related macular degeneration (AMD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today